By Katherine Hamilton
Solid Biosciences received clearance from the Food and Drug Administration for an investigational new drug application, the company said Tuesday.
The application is for SGT-212, designed to treat the degenerative disease Friedreich's ataxia. The drug is unique because it uses two routes of administration to address the illness in the cardiac region and the cerebellum.
The Charlestown, Mass.-based company expects to initiate a phase 1b clinical trial in the second half of 2025.
Shares climbed 20% to $4.70 in after-hours trading following the news.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(MORE TO FOLLOW) Dow Jones Newswires
January 07, 2025 16:40 ET (21:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.